Vir Biotechnology Reports $125.7 Million Net Loss and Decline in Revenues for Q1 2026

Vir Biotechnology, Inc. reported a net loss of $125.7 million for the first quarter of 2026, a slight increase from the $121.0 million loss recorded in the same period of 2025. Total revenues for the quarter were $(29,000), a significant decline from $3.0 million in the prior year, primarily due to a decrease in grant revenue and other income. Grant revenue fell to $12,000 from $1.2 million, largely attributed to the expiration of certain agreements with the Gates Foundation. The company’s operating expenses decreased to $132.3 million from $142.6 million, driven by reduced research and development costs, which fell to $108.9 million from $118.6 million.

In terms of financial position, Vir Biotechnology's total assets increased to $1.03 billion as of March 31, 2026, compared to $1.00 billion at the end of 2025. The company’s cash and cash equivalents rose to $274.2 million, up from $232.2 million, bolstered by a follow-on public offering completed in February 2026 that generated approximately $162.3 million in net proceeds. The company’s accumulated deficit also increased to $1.32 billion, reflecting ongoing investments in its clinical programs.

Strategically, Vir Biotechnology has made significant advancements in its clinical pipeline, particularly in the treatment of chronic hepatitis delta and oncology. The company is actively conducting the ECLIPSE registrational program, with three trials initiated for the combination of tobevibart and elebsiran. Additionally, Vir Biotechnology entered into a global collaboration with Astellas US LLC to co-develop the investigational dual-masked T-cell engager VIR-5500 for prostate cancer, which is currently in Phase 1 development.

Operationally, the company reported a decrease in its employee headcount, which contributed to lower personnel-related expenses. The total number of shares outstanding increased to 161.2 million as of March 31, 2026, following the public offering. The company continues to focus on advancing its clinical programs while managing its cash resources effectively, with a belief that its current financial position will support operations for at least the next twelve months. Looking ahead, Vir Biotechnology anticipates further developments in its clinical trials and potential regulatory submissions, although it acknowledges the inherent risks and uncertainties associated with drug development.